Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Propanc Biopharma Inc. (PPCB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,026
  • Shares Outstanding, K 10,390
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,870 K
  • 36-Month Beta 8.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 12/07/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0900 +544.44%
on 11/28/17
0.7700 -24.68%
on 12/08/17
+0.4880 (+530.43%)
since 11/08/17
3-Month
0.0900 +544.44%
on 11/28/17
0.7700 -24.68%
on 12/08/17
+0.2575 (+79.84%)
since 09/08/17
52-Week
0.0900 +544.44%
on 11/28/17
3.8250 -84.84%
on 01/24/17
-2.1700 (-78.91%)
since 12/08/16

Most Recent Stories

More News
Biotech's Flying Under The Radar

Biotech investors spend a ton of time considering what the cure for cancer could be or the next invention that could eliminate a rare disease. It's difficult to keep track of the advancements and developments...

ESPR : 56.97 (+4.21%)
AEZS : 2.23 (+3.24%)
PPCB : 0.5800 (+38.10%)
GERN : 2.03 (+2.01%)
CPRX : 4.00 (-4.08%)
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials

Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering...

PPCHD : 1.2000 (+20.00%)
PPCB : 0.5800 (+38.10%)
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials

MELBOURNE, Australia , Dec. 4, 2017 /PRNewswire/ --  Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development...

PPCB : 0.5800 (+38.10%)
Propanc Biopharma to Present at the 10th Annual LD Micro Main Event

MELBOURNE, AUSTRALIA--(Marketwired - November 27, 2017) - Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development...

PPCHD : 1.2000 (+20.00%)
PPCB : 0.5800 (+38.10%)
Reaching Regulatory Milestones in Biotech

LAS VEGAS, November 9, 2017 /PRNewswire/ --

STML : 14.85 (-0.83%)
KURA : 14.90 (+5.30%)
PPCB : 0.5800 (+38.10%)
JUNO : 58.65 (+3.38%)
VSTM : 4.33 (+9.07%)
Biotech Companies With Advantageous Tech for Cancer Patients

LAS VEGAS, November 1, 2017 /PRNewswire/ --

IMGN : 6.20 (+2.48%)
PPCB : 0.5800 (+38.10%)
INO : 4.50 (+2.74%)
VSTM : 4.33 (+9.07%)
Biotech Companies With Advantageous Tech for Cancer Patients

There has been progression in both, earlier detection of cancer and cancer therapies. Despite this headway, cancer remains a worldwide healthcare problem. Cancer is the second leading cause of death globally...

IMGN : 6.20 (+2.48%)
PPCB : 0.5800 (+38.10%)
INO : 4.50 (+2.74%)
VSTM : 4.33 (+9.07%)
Propanc Biopharma Submits Orphan Drug Designation Request to the US Food and Drug Administration for Treatment of Ovarian Cancer

MELBOURNE, AUSTRALIA--(Marketwired - October 25, 2017) - Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development...

PPCHD : 1.2000 (+20.00%)
PPCB : 0.5800 (+38.10%)
Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal

Pancreatic Proenzymes Provides For Potent Anti-Tumor Efficacy in Pancreatic and Ovarian Cancers

PPCHD : 1.2000 (+20.00%)
PPCB : 0.5800 (+38.10%)
Searching for Innovative Cancer Therapies in Biotech

LAS VEGAS, October 5, 2017 /PRNewswire/ --

ECYT : 4.94 (+3.35%)
IMGN : 6.20 (+2.48%)
KURA : 14.90 (+5.30%)
PPCB : 0.5800 (+38.10%)
MBRX : 1.80 (-4.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Key Turning Points

2nd Resistance Point 0.9403
1st Resistance Point 0.7602
Last Price 0.5800
1st Support Level 0.4097
2nd Support Level 0.2393

See More

52-Week High 3.8250
Fibonacci 61.8% 2.3982
Fibonacci 50% 1.9575
Fibonacci 38.2% 1.5168
Last Price 0.5800
52-Week Low 0.0900

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.